NCT03486119View on ClinicalTrials.gov

A Study for Identification of Predictive Immune Biomarker in Peripheral Blood for Nivolumab Therapy in NSCLC Patients

CompletedOBSERVATIONAL
Enrollment

60

Participants

Timeline

Start Date

February 5, 2018

Primary Completion Date

July 7, 2020

Study Completion Date

July 7, 2020

Conditions
Non -Small Cell Lung Cancer
Interventions
OTHER

nivolumab

Subjects will be treated with 3mg/kg in nivolumab IV every 2 weeks for a maximum of 12 months.

Trial Locations (1)

03722

Department of Oncology, Yonsei University College of Medicine, Seoul

All Listed Sponsors
lead

Yonsei University

OTHER

NCT03486119 - A Study for Identification of Predictive Immune Biomarker in Peripheral Blood for Nivolumab Therapy in NSCLC Patients | Biotech Hunter | Biotech Hunter